Health, mostly. 518 US adults were asked about a month after their first dose. They named improving overall health and wellbeing at 83.8%, physical functioning at 58.3%, and confidence or appearance outside work at 51.4% [1]. The public conversation about these drugs assumes the third answer is the first one. The people taking them rank it below the other two.
What stops them is money, and specifically coverage. Health insurance was named as a barrier by 90% against 57.7% for the cost of treatment itself. That gap matters here. A self-pay price is what remains when the coverage question is settled badly. covered and still not treated walks the same problem from the payer’s side.
Who arrives, and what they arrived with
Participants reported substantial impairment in physical functioning and psychosocial wellbeing at the point of starting, along with high internalized weight bias. Nearly half had already tried and failed to lose weight or keep it off through diet and exercise, so this is largely not a first attempt.
Norwegian registry data puts the same point on a whole population. At least one comorbidity was recorded for 71% to 78% of people starting a weight-loss drug, against roughly half of matched controls. Opioid and antidepressant use ran about double [3]. The buyer this market describes in its advertising and the buyer in the registry are not the same person.
What coverage is worth to the people who want it
The same 518 respondents were asked about employment. Of them, 52.3% said coverage for obesity medication would make them consider changing jobs [2].
Read that as a price signal rather than a labor statistic. The sample is everyone who already obtained the drug. It measures how much the people who got past the barrier valued the thing that let them. half would change jobs to get it covered sets out the limits of that reading.
How they got here
Roughly one in eight arrived by switching. Of the respondents, 12.7% had previously taken semaglutide, which is a flow worth knowing when comparing products against each other.
A brand comparison built on people who switched is not a comparison of the brands, as the super-responder analysis shows. Half the people in this survey were already past one failed attempt before they started this one.
The provenance question
Both PERCEPTIONS papers survey people initiating one manufacturer’s drug, and neither abstract states its funding. They share the same 518 respondents, so they are one survey rather than two independent findings.
Nothing in the results looks implausible. A reader should know the provenance is unstated rather than assume it either way. That is the rule applied in who funds the comparison you are reading. What people report after longer on treatment is in what patients said when asked.